For the first time in history, 100 percent of patients were cured in a clinical trial of a cancer drug. The new drug, Dusterlimab, was given to 12 cancer patients, all of whom had their tumors disappear from the rectum after six months of treatment.

Line Burger Cancer Research Center oncologist. Hannah Sanof sees the results as a cause for great optimism. “Immune therapy is a great way to cure colon cancer,” he said in an editorial in the New England Journal of Medicine.

After so many days of chemotherapy, the treatment was radiation and then surgical removal of the colon. These patients were given dusterlimab every three consecutive weeks for six months. Dusterlimab is manufactured by Tesaro, a biotech company in Massachusetts. However, this company bought GlaxoSmithKline in 2019.

This progress has become a beacon of new hope for cancer patients.